{"protocolSection":{"identificationModule":{"nctId":"NCT01179672","orgStudyIdInfo":{"id":"13649"},"secondaryIdInfos":[{"id":"F1J-MC-HMGV","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study in Participants With Diabetic Peripheral Neuropathic Pain in China","officialTitle":"Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China: Duloxetine Versus Placebo"},"statusModule":{"statusVerifiedDate":"2014-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2011-04"},"primaryCompletionDateStruct":{"date":"2013-08","type":"ACTUAL"},"completionDateStruct":{"date":"2013-08","type":"ACTUAL"},"studyFirstSubmitDate":"2010-08-10","studyFirstSubmitQcDate":"2010-08-10","studyFirstPostDateStruct":{"date":"2010-08-11","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-06-12","resultsFirstSubmitQcDate":"2014-06-12","resultsFirstPostDateStruct":{"date":"2014-07-14","type":"ESTIMATED"},"lastUpdateSubmitDate":"2014-10-03","lastUpdatePostDateStruct":{"date":"2014-10-13","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this trial is to assess the efficacy of duloxetine 60 milligrams (mg) once daily (QD) compared with placebo, on the change in pain severity from baseline to 12 weeks as measured by the weekly mean of the daily pain scores recorded in the participant's diary in participants with diabetic peripheral neuropathic pain."},"conditionsModule":{"conditions":["Diabetic Neuropathy, Painful"],"keywords":["Diabetic Peripheral Neuropathic Pain"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":405,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Duloxetine","type":"EXPERIMENTAL","interventionNames":["Drug: Duloxetine"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"Duloxetine","description":"30 mg administered orally (po), QD for 1 week; 60 mg administered po, QD for remaining 11 weeks; 30 mg administered po, QD for 1 week during taper period","armGroupLabels":["Duloxetine"],"otherNames":["Cymbalta","LY248686"]},{"type":"DRUG","name":"Placebo","description":"Administered po, QD for 12 weeks; administered po, QD for 1 week during taper period","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Mean Change From Baseline at 12-Week Endpoint in the Weekly Mean of Pain Severity Score","description":"24-hour average pain severity scores were recorded daily by the participant on an 11-point Likert scale, an ordinal scale, with scores ranging from 0 (no pain) to 10 (worst possible pain). The weekly mean was calculated. A negative change indicated an improvement in participant's condition. Least squares (LS) mean was calculated using mixed model repeating measures (MMRM) and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.","timeFrame":"Baseline, 12 weeks"}],"secondaryOutcomes":[{"measure":"Mean Change From Baseline at 12-Week Endpoint in Weekly Mean of Night Pain and Worst Pain","description":"24-hour average night pain and worst pain severity scores were recorded daily on an 11-point Likert scale, an ordinal scale, with scores ranging from 0 (no pain) to 10 (worst possible pain). A negative change indicated an improvement in the participant's condition. LS mean was calculated using MMRM and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as the baseline score and baseline score-by-visit interaction.","timeFrame":"Baseline, 12 weeks"},{"measure":"Mean Change From Baseline at 12-Week Endpoint in the BPI-Severity Scale","description":"BPI-Severity Scale was a self-reported scale that measured the severity of pain based on the average pain over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). A negative change indicated an improvement in the participant's condition. LS mean was calculated using MMRM and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.","timeFrame":"Baseline, 12 weeks"},{"measure":"Mean Change From Baseline at 12-Week Endpoint in the CGI-S Scale","description":"CGI-S was administered by the investigator in the presence of the participant and measured the severity of illness at the time of assessment compared with start of treatment; CGI-S scores ranged from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). A negative change indicated an improvement in the participant's condition. LS mean was calculated using MMRM and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.","timeFrame":"Baseline, 12 weeks"},{"measure":"Patient Global Impression of Improvement (PGI-I) Scale at 12-Week Endpoint","description":"PGI-I was self-reported and measured a participant's perception of improvement at the time of assessment compared with the start of treatment. Scores ranged from 1 (very much better) to 7 (very much worse). LS mean was calculated using MMRM and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.","timeFrame":"12 weeks"},{"measure":"Mean Change From Baseline at 12-Week Endpoint in the Sensory Subscale of the SF-MPQ","description":"SF-MPQ was a self-reported instrument that consisted of 11 sensory descriptors describing pain. The descriptors were rated on an intensity scale from 0 (none), 1 (mild), 2 (moderate) or 3 (severe). Three (3) pain scores were derived from the sum of the intensity rank values of the words chosen for sensory descriptors. The SF-MPQ sensory subscale was the sum of the 11 scores (ranged from 0 to 33, with 33 being the worst pain). A negative change indicates an improvement. LS mean was calculated using analysis of covariance (ANCOVA) adjusted for treatment, pooled investigator and baseline.","timeFrame":"Baseline, 12 weeks"},{"measure":"Percentage of Participants Who Experience Equal to or Greater Than 30%, 50% or 75% Reduction From Baseline at 12-Week Endpoint in Weekly Mean of Average Daily Pain","description":"24-hour self-assessment of average daily pain was recorded in the participants diary based on an 11 point Likert scale with scores ranging from 0 (no pain) to 10 (worst possible pain). Percentage of participants was calculated as: (number of participants with 30% \\[or 50% or 75%\\] reduction in average daily pain) divided by (number of participants) multiplied by 100.","timeFrame":"Baseline, 12 weeks"},{"measure":"Percentage of Participants Who Experienced Equal to or Greater Than 30%, 50% or 75% Reduction From Baseline at 12-week Endpoint in BPI-Severity Average Pain Score","description":"BPI-Severity scale was a self-reported scale that measured the severity of pain based on the average pain experienced over the past 24 hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). A negative change indicated an improvement in the participant's condition. Percentage of participants was calculated as: (number of participants with 30% \\[or 50% or 75%\\] reduction in BPI-Severity average pain) divided by (number of participants) multiplied by 100.","timeFrame":"Baseline, 12 weeks"},{"measure":"Mean Change From Baseline at 12-week Endpoint in the BPI Interference Score","description":"BPI-Interference Score was a self-reported scale that measured the interference of pain based on the average of the 7 questions assessing the interference of pain for general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. The average interference scores ranged from 0 (does not interfere) to 10 (completely interferes). A negative change indicates an improvement in the participant's condition. LS means was calculated using MMRM and adjusted treatment, pooled investigator, visit, and treatment-by-visit interaction, baseline score and baseline score-by-visit interaction.","timeFrame":"Baseline, 12 weeks"},{"measure":"Mean Change From Baseline at 12 Week Endpoint in the SDS Total Score","description":"SDS was self-reported and used to assess the effect of the participant's symptoms on their work (Item 1), social life (Item 2), and family life (Item 3). Each item was measured on a 0 (not at all) to 10 (extremely) point scale with higher values indicating greater disruption. SDS total score was the sum of the 3 items and ranged from 0 to 30, with higher values indicating greater disruption in the participant's work/social/family life. Scores ≥5 were associated with significant functional impairment. A negative change indicated an improvement in the participant's condition. LS mean was adjusted using MMRM and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, baseline score and baseline score-by-visit interaction.","timeFrame":"Baseline, 12 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Present with pain due to bilateral peripheral neuropathy\n\n  * Participants must have pain caused by Type 1 or Type 2 diabetes mellitus\n  * Pain must begin in the feet with relatively symmetrical onset\n  * Daily pain should be present for at least 6 months\n  * Diagnosis must be confirmed by a score of at least 3 on the Michigan Neuropathy Screening Inventory (MNSI)\n* Females must test negative for a serum pregnancy test at Screening. Females of child-bearing potential (who are not surgically sterilized and between menarche and 1 year postmenopause) must agree to use a medically acceptable and reliable means of birth control, during the study and for 1 month following the last study dose.\n* Stable glycemic control as assessed by a physician investigator and a glycosylated hemoglobin (HbA1c) \\<12% before randomization\n* Score of greater than or equal to 4 on the Brief Pain Inventory (BPI) 24-hour average pain item at Screening.\n* Full completion of the daily diaries for at least 80% of the days between the second and third time you come to the hospital (Screening).\n\nExclusion Criteria:\n\n* Currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational drug or device or off-label use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study\n* Current (less than or equal to 1 year) Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) Axis I diagnosis of major depressive disorder, dysthymia, anxiety disorders (excluding phobias), alcohol or eating disorders as determined by the Mini-International Neuropsychiatric Interview (MINI) or a previous diagnosis\n* DSM-IV diagnosis of mania, bipolar disorder, or psychosis determined either by participant history or by diagnosis using specific MNSI modules\n* Serious or unstable cardiovascular, hepatic, renal, respiratory, or hematologic illness, symptomatic peripheral vascular disease, or other medical condition or psychological conditions that in the opinion of investigator would compromise participation or be likely to lead to hospitalization during the course of the study.\n* At Screening alanine transaminase (ALT) greater than 2 times upper limit of normal (ULN), based on central laboratory reference ranges times ULN, based on central laboratory reference ranges\n* Prior renal transplant, current renal dialysis, or serum creatinine laboratory value \\>1.5 times ULN, based on central laboratory reference ranges at Screening.\n* Historical exposure to drugs known to cause neuropathy, or a history of a medical condition, including pernicious anemia and hypothyroidism, that could have been responsible for neuropathy\n* Pain that cannot be clearly differentiated from or conditions that interfere with the assessment of the diabetic neuropathy pain. Examples of painful conditions that could be confused with diabetic neuropathy pain include peripheral vascular disease, neurological disorders unrelated to diabetic neuropathy, skin condition in the area of the neuropathy that could alter sensation, other painful conditions\n* Participants who have previously completed or withdrawn from this study or have been previously treated with duloxetine, including participants who participated in study F1J-MC-HMEQ (NCT00408993), even those in the placebo arm\n* Participants taking excluded medications that cannot be stopped at Screening\n* Treatment with a monoamine oxidase inhibitor (MAOI) or fluoxetine within 30 days of the third Screening\n* Participants with a positive Hepatitis B surface antigen and/or Hepatitis C antibody are to be excluded if they have any of the following:\n\n  * Hepatic dysfunction as determined by the investigator or\n  * Clinical manifestations of liver disease within the previous year such as unexplained pruritus, unexplained dark urine, jaundice, unexplained right upper quadrant tenderness, unexplained \"flu-like\" symptoms or\n  * Aspartate transaminase (AST), ALT, or bilirubin above the normal reference range.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Beijing","zip":"100730","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bengbu","zip":"233004","country":"China","geoPoint":{"lat":32.94083,"lon":117.36083}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Changchun","zip":"130021","country":"China","geoPoint":{"lat":43.88,"lon":125.32278}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Chengdu","zip":"610072","country":"China","geoPoint":{"lat":30.66667,"lon":104.06667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Chongqing","country":"China","geoPoint":{"lat":29.56026,"lon":106.55771}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Guangzhou","zip":"510515","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Jinan","zip":"250001","country":"China","geoPoint":{"lat":36.66833,"lon":116.99722}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Nanjin","zip":"210006","country":"China","geoPoint":{"lat":29.98497,"lon":106.26529}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Qingdao","zip":"266003","country":"China","geoPoint":{"lat":36.06488,"lon":120.38042}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Shanghai","zip":"200040","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Shantou","zip":"515041","country":"China","geoPoint":{"lat":23.35489,"lon":116.67876}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Shijiazhuang","zip":"050051","country":"China","geoPoint":{"lat":38.04139,"lon":114.47861}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Tianjin","zip":"300211","country":"China","geoPoint":{"lat":39.14222,"lon":117.17667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Xi'an","zip":"710061","country":"China","geoPoint":{"lat":34.25833,"lon":108.92861}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Yueyang","zip":"414000","country":"China","geoPoint":{"lat":29.37455,"lon":113.09481}}]},"referencesModule":{"references":[{"pmid":"25939897","type":"DERIVED","citation":"Gao Y, Guo X, Han P, Li Q, Yang G, Qu S, Yue L, Wang CN, Skljarevski V, Duenas H, Raskin J, Gu L. Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo. Int J Clin Pract. 2015 Sep;69(9):957-66. doi: 10.1111/ijcp.12641. Epub 2015 May 4."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Participants tapered off study drug after either completing the 12 weeks of treatment or discontinued treatment early.","groups":[{"id":"FG000","title":"Duloxetine","description":"30 milligrams (mg) duloxetine capsule administered orally, once daily (QD) during Week 1 then 60 mg duloxetine capsule orally, QD for the remaining 11 weeks of treatment. After a total 12 weeks of treatment or early discontinuation participants tapered off study drug (30 mg duloxetine capsule QD) for 1 week during taper."},{"id":"FG001","title":"Placebo","description":"Placebo administered orally, QD for 12 weeks of the treatment and orally, QD for 1 week during taper."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"203"},{"groupId":"FG001","numSubjects":"202"}]},{"type":"Received at Least 1 Dose of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"202"},{"groupId":"FG001","numSubjects":"202"}]},{"type":"Entered Taper","achievements":[{"groupId":"FG000","numSubjects":"181"},{"groupId":"FG001","numSubjects":"177"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"173"},{"groupId":"FG001","numSubjects":"176"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"30"},{"groupId":"FG001","numSubjects":"26"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"8"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"12"}]},{"type":"Entry Criteria Not Met","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All randomized participants.","groups":[{"id":"BG000","title":"Duloxetine","description":"30 mg duloxetine capsule administered orally, QD during Week 1 then 60 mg duloxetine capsule orally, QD for remaining 11 weeks of the treatment. After a total 12 weeks of treatment or early discontinuation, participants tapered off study drug (30 mg duloxetine capsule orally, QD) for 1 week during taper."},{"id":"BG001","title":"Placebo","description":"Placebo administered orally, QD for 12 weeks of the treatment and orally, QD for 1 week during taper."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"203"},{"groupId":"BG001","value":"202"},{"groupId":"BG002","value":"405"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"61.56","spread":"9.65"},{"groupId":"BG001","value":"61.17","spread":"9.42"},{"groupId":"BG002","value":"61.37","spread":"9.52"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"112"},{"groupId":"BG001","value":"111"},{"groupId":"BG002","value":"223"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"91"},{"groupId":"BG001","value":"91"},{"groupId":"BG002","value":"182"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"203"},{"groupId":"BG001","value":"202"},{"groupId":"BG002","value":"405"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"203"},{"groupId":"BG001","value":"202"},{"groupId":"BG002","value":"405"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"China","categories":[{"measurements":[{"groupId":"BG000","value":"203"},{"groupId":"BG001","value":"202"},{"groupId":"BG002","value":"405"}]}]}]},{"title":"Diabetes Disease Characteristics-Types of Diabetes","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Type I Diabetes","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}]}]},{"title":"Type II Diabetes","categories":[{"measurements":[{"groupId":"BG000","value":"200"},{"groupId":"BG001","value":"199"},{"groupId":"BG002","value":"399"}]}]}]},{"title":"Diabetes Disease Characteristics","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"title":"Duration of Diabetes","categories":[{"measurements":[{"groupId":"BG000","value":"11.53","spread":"6.81"},{"groupId":"BG001","value":"11.38","spread":"7.47"},{"groupId":"BG002","value":"11.45","spread":"7.14"}]}]},{"title":"Duration of Diabetic Neuropathy","categories":[{"measurements":[{"groupId":"BG000","value":"3.47","spread":"3.91"},{"groupId":"BG001","value":"3.07","spread":"3.13"},{"groupId":"BG002","value":"3.27","spread":"3.55"}]}]},{"title":"Duration of Diabetic Neuropathy Pain","categories":[{"measurements":[{"groupId":"BG000","value":"3.06","spread":"3.70"},{"groupId":"BG001","value":"2.59","spread":"2.69"},{"groupId":"BG002","value":"2.83","spread":"3.24"}]}]}]},{"title":"Weekly Mean of 24-Hour Average Pain","description":"Participants measured their pain on an 11-point Likert scale that was completed daily. The scale ranged from 0 (no pain) to 10 (worst possible pain). The participant-recorded average pain due to diabetic neuropathy over the previous 24 hours.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5.72","spread":"1.72"},{"groupId":"BG001","value":"5.62","spread":"1.66"},{"groupId":"BG002","value":"5.67","spread":"1.69"}]}]}]},{"title":"Brief Pain Inventory (BPI)-Severity Average Pain in the Last Week","description":"BPI-Severity Modified Short Form Severity was a self-reported scale that measured the severity of pain. Severity scores ranged from 0 (no pain) to 10 (pain as bad as you could imagine). There were 4 questions assessing the severity for worst pain, least pain, average pain, and the pain right now.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5.97","spread":"1.70"},{"groupId":"BG001","value":"5.86","spread":"1.64"},{"groupId":"BG002","value":"5.91","spread":"1.67"}]}]}]},{"title":"Clinical Global Impression of Severity (CGI-S)","description":"Number of participants analyzed was: Duloxetine treatment =126 and Placebo=136. Data from 9 sites were not included in baseline analysis due to wrong questionnaire used. CSI-S was administered by the investigator in the presence of the participant and measured severity of illness at baseline with scores ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill participants).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4.76","spread":"1.22"},{"groupId":"BG001","value":"4.66","spread":"1.07"},{"groupId":"BG002","value":"4.71","spread":"1.14"}]}]}]},{"title":"Short Form-McGill Pain Questionnaire (SF-MPQ), Sensory Portion Total Score","description":"SF-MPQ sensory portion was a self-reported instrument consisting of 11 sensory descriptors describing pain, each rated on an intensity scale from 0 (none) to 3 (severe). Total scores ranged from 0 to 33.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12.24","spread":"6.39"},{"groupId":"BG001","value":"11.81","spread":"5.52"},{"groupId":"BG002","value":"12.02","spread":"5.97"}]}]}]},{"title":"BPI-Interference Average Score","description":"BPI-Interference Score was self-reported scale that measured interference of pain based on the average of the 7 questions assessing the interference of pain for general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. The average interference scores ranged from 0 (does not interfere) to 10 (completely interferes).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4.38","spread":"2.29"},{"groupId":"BG001","value":"4.08","spread":"2.30"},{"groupId":"BG002","value":"4.23","spread":"2.30"}]}]}]},{"title":"Sheehan Disability Scale (SDS) Total Score","description":"SDS was self-reported and used to assess the effect of the participant's symptoms on their work (Item 1), social life (Item 2), and family life (Item 3). Each item was measured on a 0 (not at all) to 10 (extremely) point scale with higher values indicating greater disruption. SDS Total Score was the sum of the 3 items and ranged from 0 to 30 with higher values indicating greater disruption in the participant's work/social/family life. Scores ≥5 were associated with significant functional impairment.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11.16","spread":"7.59"},{"groupId":"BG001","value":"10.54","spread":"7.31"},{"groupId":"BG002","value":"10.85","spread":"7.45"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change From Baseline at 12-Week Endpoint in the Weekly Mean of Pain Severity Score","description":"24-hour average pain severity scores were recorded daily by the participant on an 11-point Likert scale, an ordinal scale, with scores ranging from 0 (no pain) to 10 (worst possible pain). The weekly mean was calculated. A negative change indicated an improvement in participant's condition. Least squares (LS) mean was calculated using mixed model repeating measures (MMRM) and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.","populationDescription":"Intent-to-treat (ITT) principle was applied: All participants with a baseline and 12-week 24-hour average pain score based on the randomized group were analyzed.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks","groups":[{"id":"OG000","title":"Duloxetine","description":"30 mg duloxetine capsule administered orally, QD during Week 1, then 60 mg duloxetine capsule orally QD for remaining 11 weeks of the treatment. After a total 12 weeks of treatment or early discontinuation, participants tapered off study drug (30 mg duloxetine capsule orally, QD) for 1 week during taper."},{"id":"OG001","title":"Placebo","description":"Placebo administered orally, QD for 12 weeks of the treatment and orally, QD for 1 week during taper."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"172"},{"groupId":"OG001","value":"173"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.40","spread":"0.14"},{"groupId":"OG001","value":"-1.97","spread":"0.14"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.030","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"-0.43","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.82","ciUpperLimit":"-0.04"}]},{"type":"SECONDARY","title":"Mean Change From Baseline at 12-Week Endpoint in Weekly Mean of Night Pain and Worst Pain","description":"24-hour average night pain and worst pain severity scores were recorded daily on an 11-point Likert scale, an ordinal scale, with scores ranging from 0 (no pain) to 10 (worst possible pain). A negative change indicated an improvement in the participant's condition. LS mean was calculated using MMRM and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as the baseline score and baseline score-by-visit interaction.","populationDescription":"ITT principle was applied: All participants with a baseline and 12-week 24-hour night pain score and worst pain score based on the randomized group were analyzed.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks","groups":[{"id":"OG000","title":"Duloxetine","description":"30 mg duloxetine capsule administered orally, QD during Week 1, then 60 mg duloxetine capsule orally, QD for remaining 11 weeks of the treatment. After a total 12 weeks of treatment or early discontinuation, participants tapered off study drug (30 mg duloxetine capsule orally, QD) for 1 week during taper."},{"id":"OG001","title":"Placebo","description":"Placebo administered orally, QD for 12 weeks of the treatment and orally, QD for 1 week during taper."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"172"},{"groupId":"OG001","value":"173"}]}],"classes":[{"title":"Night Pain","categories":[{"measurements":[{"groupId":"OG000","value":"-2.65","spread":"0.15"},{"groupId":"OG001","value":"-2.11","spread":"0.15"}]}]},{"title":"Worst Pain","categories":[{"measurements":[{"groupId":"OG000","value":"-2.80","spread":"0.16"},{"groupId":"OG001","value":"-2.25","spread":"0.17"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.008","pValueComment":"P-value is for mean change from baseline to 12-week endpoint in night pain.","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"-0.54","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.95","ciUpperLimit":"-0.14"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.017","pValueComment":"P-value is for mean change from baseline to 12 week endpoint in worst pain.","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"-0.55","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.00","ciUpperLimit":"-0.10"}]},{"type":"SECONDARY","title":"Mean Change From Baseline at 12-Week Endpoint in the BPI-Severity Scale","description":"BPI-Severity Scale was a self-reported scale that measured the severity of pain based on the average pain over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). A negative change indicated an improvement in the participant's condition. LS mean was calculated using MMRM and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.","populationDescription":"ITT principle was applied: All participants with a baseline and 12-week, 24-hour BPI-Severity score based on the randomized group were analyzed.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks","groups":[{"id":"OG000","title":"Duloxetine","description":"30 mg duloxetine capsule administered orally, QD during Week 1, then 60 mg duloxetine capsule orally, QD for remaining 11 weeks of the treatment. After a total 12 weeks of treatment or early discontinuation, participants tapered off study drug (30 mg duloxetine capsule orally, QD) for 1 week during taper."},{"id":"OG001","title":"Placebo","description":"Placebo administered orally, QD for 12 weeks of the treatment and orally, QD for 1 week during taper."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"175"},{"groupId":"OG001","value":"173"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.50","spread":"0.15"},{"groupId":"OG001","value":"-2.00","spread":"0.15"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.016","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"-0.50","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.90","ciUpperLimit":"-0.09"}]},{"type":"SECONDARY","title":"Mean Change From Baseline at 12-Week Endpoint in the CGI-S Scale","description":"CGI-S was administered by the investigator in the presence of the participant and measured the severity of illness at the time of assessment compared with start of treatment; CGI-S scores ranged from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). A negative change indicated an improvement in the participant's condition. LS mean was calculated using MMRM and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.","populationDescription":"ITT principle was applied: All participants with a baseline and 12-week CGI-S score based on the randomized group were analyzed. Data from 9 sites was not included in analysis due to wrong questionnaire used.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks","groups":[{"id":"OG000","title":"Duloxetine","description":"30 mg duloxetine capsule administered orally, QD during Week 1, then 60 mg duloxetine capsule orally, QD for remaining 11 weeks of the treatment. After a total 12 weeks of treatment or early discontinuation, participants tapered off study drug (30 mg duloxetine capsule orally, QD) for 1 week during taper."},{"id":"OG001","title":"Placebo","description":"Placebo administered orally, QD for 12 weeks of the treatment and orally, QD for 1 week during taper."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"118"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.40","spread":"0.10"},{"groupId":"OG001","value":"-1.17","spread":"0.10"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.081","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"-0.23","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.48","ciUpperLimit":"0.03"}]},{"type":"SECONDARY","title":"Patient Global Impression of Improvement (PGI-I) Scale at 12-Week Endpoint","description":"PGI-I was self-reported and measured a participant's perception of improvement at the time of assessment compared with the start of treatment. Scores ranged from 1 (very much better) to 7 (very much worse). LS mean was calculated using MMRM and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.","populationDescription":"All participants with a baseline and 12-week PGI-I score.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"12 weeks","groups":[{"id":"OG000","title":"Duloxetine","description":"30 mg duloxetine capsule administered orally, QD during Week 1, then 60 mg duloxetine capsule orally, QD for remaining 11 weeks of the treatment. After a total 12 weeks of treatment or early discontinuation, participants tapered off study drug (30 mg duloxetine capsule orally, QD) for 1 week during taper."},{"id":"OG001","title":"Placebo","description":"Placebo administered orally, QD for 12 weeks of the treatment and orally, QD for 1 week during taper."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"173"},{"groupId":"OG001","value":"176"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.44","spread":"0.07"},{"groupId":"OG001","value":"2.65","spread":"0.07"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.034","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"-0.21","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.40","ciUpperLimit":"-0.02"}]},{"type":"SECONDARY","title":"Mean Change From Baseline at 12-Week Endpoint in the Sensory Subscale of the SF-MPQ","description":"SF-MPQ was a self-reported instrument that consisted of 11 sensory descriptors describing pain. The descriptors were rated on an intensity scale from 0 (none), 1 (mild), 2 (moderate) or 3 (severe). Three (3) pain scores were derived from the sum of the intensity rank values of the words chosen for sensory descriptors. The SF-MPQ sensory subscale was the sum of the 11 scores (ranged from 0 to 33, with 33 being the worst pain). A negative change indicates an improvement. LS mean was calculated using analysis of covariance (ANCOVA) adjusted for treatment, pooled investigator and baseline.","populationDescription":"ITT principle was applied: All participants with a baseline and 12 weeks SF-MPQ score based on the randomized group were analyzed; last observation carried forward (LOCF).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks","groups":[{"id":"OG000","title":"Duloxetine","description":"30 mg duloxetine capsule administered orally, QD during Week 1, then 60 mg duloxetine capsule orally, QD for remaining 11 weeks of the treatment. After a total 12 weeks of treatment or early discontinuation, participants tapered off study drug (30 mg duloxetine capsule orally, QD) for 1 week during taper"},{"id":"OG001","title":"Placebo","description":"Placebo administered orally, QD for 12 weeks of the treatment and orally, QD for 1 week during taper."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"188"},{"groupId":"OG001","value":"180"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.45","spread":"0.36"},{"groupId":"OG001","value":"-5.33","spread":"0.39"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.022","statisticalMethod":"ANCOVA","statisticalComment":"ANCOVA adjusted for treatment, pooled investigator and baseline.","paramType":"Mean Difference (Final Values)","paramValue":"-1.12","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.07","ciUpperLimit":"-0.16"}]},{"type":"SECONDARY","title":"Percentage of Participants Who Experience Equal to or Greater Than 30%, 50% or 75% Reduction From Baseline at 12-Week Endpoint in Weekly Mean of Average Daily Pain","description":"24-hour self-assessment of average daily pain was recorded in the participants diary based on an 11 point Likert scale with scores ranging from 0 (no pain) to 10 (worst possible pain). Percentage of participants was calculated as: (number of participants with 30% \\[or 50% or 75%\\] reduction in average daily pain) divided by (number of participants) multiplied by 100.","populationDescription":"All participants with a baseline and postbaseline 24-hour average pain score.","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline, 12 weeks","groups":[{"id":"OG000","title":"Duloxetine","description":"30 mg duloxetine capsule administered orally, QD during Week 1, then 60 mg duloxetine capsule orally, QD for remaining 11 weeks of the treatment. After a total 12 weeks of treatment or early discontinuation, participants tapered off study drug (30 mg duloxetine capsule orally, QD) for 1 week during taper."},{"id":"OG001","title":"Placebo","description":"Placebo administered orally, QD for 12 weeks of the treatment and orally, QD for 1 week during taper."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"198"}]}],"classes":[{"title":"≥30% Reduction","categories":[{"measurements":[{"groupId":"OG000","value":"61.5"},{"groupId":"OG001","value":"49.0"}]}]},{"title":"≥50% Reduction","categories":[{"measurements":[{"groupId":"OG000","value":"42.0"},{"groupId":"OG001","value":"28.8"}]}]},{"title":"≥75% Reduction","categories":[{"measurements":[{"groupId":"OG000","value":"14.5"},{"groupId":"OG001","value":"9.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.014","pValueComment":"P-value is for ≥30% reduction in 24-hour average pain.","statisticalMethod":"Cochran-Mantel-Haenszel","statisticalComment":"Cochran-Mantel-Haenszel test was stratified by pooled investigator."},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.006","pValueComment":"P-value is for ≥50% reduction in 24-hour average pain.","statisticalMethod":"Cochran-Mantel-Haenszel","statisticalComment":"Cochran-Mantel-Haenszel test was stratified by pooled investigator."},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.193","pValueComment":"P-value is for ≥75% reduction in 24-hour average pain.","statisticalMethod":"Cochran-Mantel-Haenszel","statisticalComment":"Cochran-Mantel-Haenszel test was stratified by pooled investigator."}]},{"type":"SECONDARY","title":"Percentage of Participants Who Experienced Equal to or Greater Than 30%, 50% or 75% Reduction From Baseline at 12-week Endpoint in BPI-Severity Average Pain Score","description":"BPI-Severity scale was a self-reported scale that measured the severity of pain based on the average pain experienced over the past 24 hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). A negative change indicated an improvement in the participant's condition. Percentage of participants was calculated as: (number of participants with 30% \\[or 50% or 75%\\] reduction in BPI-Severity average pain) divided by (number of participants) multiplied by 100.","populationDescription":"All participants with a baseline and postbaseline BPI-Severity average pain scores.","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline, 12 weeks","groups":[{"id":"OG000","title":"Duloxetine","description":"30 mg duloxetine capsule administered orally, QD during Week 1, then 60 mg duloxetine capsule orally, QD for remaining 11 weeks of the treatment. After a total 12 weeks of treatment or early discontinuation, participants tapered off study drug (30 mg duloxetine capsule orally, QD) for 1 week during taper."},{"id":"OG001","title":"Placebo","description":"Placebo administered orally, QD for 12 weeks of the treatment and orally, QD for 1 week during taper."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"197"}]}],"classes":[{"title":"≥30% Reduction","categories":[{"measurements":[{"groupId":"OG000","value":"63.0"},{"groupId":"OG001","value":"46.7"}]}]},{"title":"≥50% Reduction","categories":[{"measurements":[{"groupId":"OG000","value":"46.0"},{"groupId":"OG001","value":"29.4"}]}]},{"title":"≥75% Reduction","categories":[{"measurements":[{"groupId":"OG000","value":"15.0"},{"groupId":"OG001","value":"9.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.003","pValueComment":"P-value is for ≥30% reduction in 24-hour BPI-Severity average pain.","statisticalMethod":"Cochran-Mantel-Haenszel","statisticalComment":"Cochran-Mantel-Haenszel test was stratified by pooled investigator."},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.001","pValueComment":"P-value is for ≥50% reduction in 24-hour BPI-Severity average pain.","statisticalMethod":"Cochran-Mantel-Haenszel","statisticalComment":"Cochran-Mantel-Haenszel test was stratified by pooled investigator."},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.168","pValueComment":"P-value is for ≥75% reduction in 24-hour BPI-Severity average pain.","statisticalMethod":"Cochran-Mantel-Haenszel","statisticalComment":"Cochran Mantel Haenszel test was stratified by pooled investigator."}]},{"type":"SECONDARY","title":"Mean Change From Baseline at 12-week Endpoint in the BPI Interference Score","description":"BPI-Interference Score was a self-reported scale that measured the interference of pain based on the average of the 7 questions assessing the interference of pain for general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. The average interference scores ranged from 0 (does not interfere) to 10 (completely interferes). A negative change indicates an improvement in the participant's condition. LS means was calculated using MMRM and adjusted treatment, pooled investigator, visit, and treatment-by-visit interaction, baseline score and baseline score-by-visit interaction.","populationDescription":"All participants with non-missing BPI-Interference score at baseline and 12 weeks.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks","groups":[{"id":"OG000","title":"Duloxetine","description":"30 mg duloxetine capsule administered orally, QD during Week 1, then 60 mg duloxetine capsule orally, QD for remaining 11 weeks of the treatment. After a total 12 weeks of treatment or early discontinuation, participants tapered off study drug (30 mg duloxetine capsule orally, QD) for 1 week during taper."},{"id":"OG001","title":"Placebo","description":"Placebo administered orally, QD for 12 weeks of the treatment and orally, QD for 1 week during taper."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"173"},{"groupId":"OG001","value":"176"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.42","spread":"0.13"},{"groupId":"OG001","value":"-1.82","spread":"0.14"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"-0.60","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.96","ciUpperLimit":"-0.24"}]},{"type":"SECONDARY","title":"Mean Change From Baseline at 12 Week Endpoint in the SDS Total Score","description":"SDS was self-reported and used to assess the effect of the participant's symptoms on their work (Item 1), social life (Item 2), and family life (Item 3). Each item was measured on a 0 (not at all) to 10 (extremely) point scale with higher values indicating greater disruption. SDS total score was the sum of the 3 items and ranged from 0 to 30, with higher values indicating greater disruption in the participant's work/social/family life. Scores ≥5 were associated with significant functional impairment. A negative change indicated an improvement in the participant's condition. LS mean was adjusted using MMRM and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, baseline score and baseline score-by-visit interaction.","populationDescription":"All participants with non-missing SDS Total Score at baseline and 12 weeks.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks","groups":[{"id":"OG000","title":"Duloxetine","description":"30 mg duloxetine capsule administered orally, QD during Week 1, then 60 mg duloxetine capsule orally, QD for remaining 11 weeks of the treatment. After a total 12 weeks of treatment or early discontinuation, participants tapered off study drug (30 mg duloxetine capsule orally, QD) for 1 week during taper."},{"id":"OG001","title":"Placebo","description":"Placebo administered orally, QD for 12 weeks of the treatment and orally, QD for 1 week during taper."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"172"},{"groupId":"OG001","value":"175"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.36","spread":"0.40"},{"groupId":"OG001","value":"-5.09","spread":"0.42"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.020","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"-1.26","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.33","ciUpperLimit":"-0.20"}]}]},"adverseEventsModule":{"frequencyThreshold":"0","eventGroups":[{"id":"EG000","title":"Duloxetine Treatment","description":"30 mg duloxetine capsule administered orally, QD during Week 1 of the treatment; 60 mg capsule administered orally, QD for remaining 11 weeks of the treatment;","seriousNumAffected":4,"seriousNumAtRisk":202,"otherNumAffected":93,"otherNumAtRisk":202},{"id":"EG001","title":"Placebo Treatment","description":"Placebo administered orally, QD for 12 weeks of the treatment.","seriousNumAffected":3,"seriousNumAtRisk":202,"otherNumAffected":71,"otherNumAtRisk":202},{"id":"EG002","title":"Duloxetine Taper","description":"After 12 weeks of treatment or early discontinuation, 30 mg duloxetine capsule administered orally, QD for 1 week during taper.","seriousNumAffected":3,"seriousNumAtRisk":181,"otherNumAffected":8,"otherNumAtRisk":181},{"id":"EG003","title":"Placebo Taper","description":"After 12 weeks of treatment or early discontinuation, placebo administered orally, QD for 1 week during taper.","seriousNumAffected":1,"seriousNumAtRisk":177,"otherNumAffected":5,"otherNumAtRisk":177}],"seriousEvents":[{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Nodal arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Cholecystitis chronic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":177}]},{"term":"Diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Non-hodgkin's lymphoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Diabetic neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":177}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":202},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Hypoacusis","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Amaurosis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Diabetic retinopathy","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Photophobia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":202},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Visual impairment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":202},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":202},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":202},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":202},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Epigastric discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Eructation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Faeces hard","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Gastric ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":177}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Gastrointestinal disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Hiatus hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Hypoaesthesia oral","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Infrequent bowel movements","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":21,"numAtRisk":202},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":202},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Regurgitation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Tongue discolouration","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":202},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Hunger","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Sluggishness","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Thirst","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Fatty liver alcoholic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":177}]},{"term":"Hepatic lesion","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Liver injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":202},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Head injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Joint dislocation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Spinal cord injury cauda equina","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Blood bicarbonate decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Blood cholesterol decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Blood potassium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Blood potassium increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Blood pressure increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Blood triglycerides increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Blood uric acid increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Transaminases increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":202},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Dyslipidaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Hypercholesterolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Hyperlipidaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":202},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":202},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Hypertriglyceridaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Hyperuricaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":181},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":177}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":202},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Fasciitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Osteoporosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Autonomic neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Clonus","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Diabetic autonomic neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Disturbance in attention","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":17,"numAtRisk":202},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Dreamy state","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Formication","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":202},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":202},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":181},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":177}]},{"term":"Hypersomnia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Lacunar infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Lethargy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Memory impairment","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Poor quality sleep","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Sciatica","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":17,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Agitation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Dysphoria","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Fear","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Food aversion","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Illusion","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Mutism","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Nervousness","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Nightmare","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Panic attack","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Sleep disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Tic","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Pollakiuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Renal failure chronic","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Urine flow decreased","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Benign prostatic hyperplasia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":91},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":91},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":76}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Dry throat","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Dermatitis allergic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Diabetic foot","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":177}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Hyperhidrosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":202},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Night sweats","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Skin swelling","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Haemorrhoid operation","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":177}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"conditionBrowseModule":{"meshes":[{"id":"D003929","term":"Diabetic Neuropathies"}],"ancestors":[{"id":"D010523","term":"Peripheral Nervous System Diseases"},{"id":"D009468","term":"Neuromuscular Diseases"},{"id":"D009422","term":"Nervous System Diseases"},{"id":"D048909","term":"Diabetes Complications"},{"id":"D003920","term":"Diabetes Mellitus"},{"id":"D004700","term":"Endocrine System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068736","term":"Duloxetine Hydrochloride"}],"ancestors":[{"id":"D013876","term":"Thiophenes"},{"id":"D013457","term":"Sulfur Compounds"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"}]}},"hasResults":true}